While there are multiple other mechanisms including induction of tolerogenic DCs [53], our study at this stage could only reveal a correlation between improvement in NEC with Treg treatment and reduction in immune activation as represented by decreased expression of CD25 and CD80 and increased numbers of CD62L+ naïve T cells. The gene discussed is SELL; the disease is necrotizing enterocolitis.